| answer text |
<p>The Medicines and Healthcare products Regulatory Agency (MHRA) has issued reminders
for healthcare professionals that fluoroquinolones should not be used in conditions
that are not serious or improve on their own and that they should only be used for
acute episodes of chronic bronchitis and uncomplicated cystitis if other antibiotics
cannot be used.</p><p>This also includes stronger warnings about the potential side
effects of fluoroquinolones in the product information for healthcare professionals
and for patients and mandating pharmaceutical companies to issue letters to healthcare
professionals on the new restrictions and stronger warnings about these serious risks,
including signs and symptoms which can appear.</p><p> </p><p>The MHRA is working with
the National Institute for Health and Care Excellence and the British National Formulary
to promote appropriate use of fluoroquinolones and ensure that the restrictions are
aligned with United Kingdom national guidance on the antibiotic treatment of infections.</p>
|
|
